Suppr超能文献

金黄色葡萄球菌菌血症患者的院内并发症发病率高于治疗失败率。

Morbidity from in-hospital complications is greater than treatment failure in patients with Staphylococcus aureus bacteraemia.

机构信息

Department of Infectious Diseases, Austin Health, Austin Centre for Infection Research, PO Box 5555, Heidelberg, VIC, 3084, Australia.

Department of Microbiology and Immunology, University of Melbourne, Melbourne, VIC, Australia.

出版信息

BMC Infect Dis. 2018 Mar 5;18(1):107. doi: 10.1186/s12879-018-3011-2.

Abstract

BACKGROUND

Various studies have identified numerous factors associated with poor clinical outcomes in patients with Staphylococcus aureus bacteraemia (SAB). A new study was created to provide deeper insight into in-hospital complications and risk factors for treatment failure.

METHODS

Adult patients hospitalised with Staphylococcus aureus bacteraemia (SAB) were recruited prospectively into a multi-centre cohort. The primary outcome was treatment failure at 30 days (composite of all-cause mortality, persistent bacteraemia, or recurrent bacteraemia), and secondary measures included in-hospital complications and mortality at 6- and 12-months. Data were available for 222 patients recruited from February 2011 to December 2012.

RESULTS

Treatment failure at 30-days was recorded in 14.4% of patients (30-day mortality 9.5%). Multivariable analysis predictors of treatment failure included age > 70 years, Pitt bacteraemia score ≥ 2, CRP at onset of SAB > 250 mg/L, and persistent fevers after SAB onset; serum albumin at onset of SAB, receipt of appropriate empiric treatment, recent healthcare attendance, and performing echocardiography were protective. 6-month and 12-month mortality were 19.1% and 24.2% respectively. 45% experienced at least one in-hospital complication, including nephrotoxicity in 19.5%.

CONCLUSIONS

This study demonstrates significant improvements in 30-day outcomes in SAB in Australia. However, we have identified important areas to improve outcomes from SAB, particularly reducing renal dysfunction and in-hospital treatment-related complications.

摘要

背景

多项研究已经确定了许多与金黄色葡萄球菌菌血症(SAB)患者临床结局不良相关的因素。一项新的研究旨在更深入地了解院内并发症和治疗失败的危险因素。

方法

前瞻性地招募了住院的金黄色葡萄球菌菌血症(SAB)成年患者入组多中心队列。主要结局是 30 天治疗失败(包括全因死亡率、持续性菌血症或复发性菌血症),次要措施包括 6 个月和 12 个月的院内并发症和死亡率。数据来自 2011 年 2 月至 2012 年 12 月招募的 222 例患者。

结果

30 天治疗失败率为 14.4%(30 天死亡率 9.5%)。多变量分析预测治疗失败的因素包括年龄>70 岁、Pitt 菌血症评分≥2、SAB 发病时 CRP>250mg/L 以及 SAB 发病后持续发热;SAB 发病时血清白蛋白、接受适当的经验性治疗、近期医疗就诊和进行超声心动图检查具有保护作用。6 个月和 12 个月的死亡率分别为 19.1%和 24.2%。45%的患者至少发生了一次院内并发症,包括 19.5%的肾毒性。

结论

本研究表明澳大利亚 SAB 的 30 天结局有显著改善。然而,我们已经确定了改善 SAB 结局的重要领域,特别是减少肾功能障碍和院内治疗相关并发症。

相似文献

2
Risk factors and mortality of healthcare-associated and community-acquired Staphylococcus aureus bacteraemia.
Clin Microbiol Infect. 2012 Sep;18(9):862-9. doi: 10.1111/j.1469-0691.2011.03679.x. Epub 2011 Oct 14.
4
Feedback to clinicians on preventable factors can reduce hospital onset Staphylococcus aureus bacteraemia rates.
J Hosp Infect. 2011 Oct;79(2):108-14. doi: 10.1016/j.jhin.2011.04.023. Epub 2011 Jul 8.
5
Vancomycin minimum inhibitory concentration, host comorbidities and mortality in Staphylococcus aureus bacteraemia.
Clin Microbiol Infect. 2013 Dec;19(12):1163-8. doi: 10.1111/1469-0691.12168. Epub 2013 Feb 26.
8
A predictive rule for mortality of inpatients with Staphylococcus aureus bacteraemia: A classification and regression tree analysis.
Eur J Intern Med. 2014 Dec;25(10):914-8. doi: 10.1016/j.ejim.2014.10.003. Epub 2014 Oct 14.
10
Relationship between vancomycin tolerance and clinical outcomes in Staphylococcus aureus bacteraemia.
J Antimicrob Chemother. 2017 Feb;72(2):535-542. doi: 10.1093/jac/dkw453. Epub 2016 Dec 20.

引用本文的文献

1
Predictors of mortality in infections: The role of C-reactive protein, neutrophil-to-lymphocyte ratio, and platelet-to-lymphocyte ratio.
J Int Med Res. 2025 Aug;53(8):3000605251363105. doi: 10.1177/03000605251363105. Epub 2025 Aug 9.
2
3
Pathogenic spectrum and drug resistance of bloodstream infection in patients with acute myeloid leukaemia: a single centre retrospective study.
Front Cell Infect Microbiol. 2024 Jun 7;14:1390053. doi: 10.3389/fcimb.2024.1390053. eCollection 2024.
4
Ceftaroline in CNS and ocular infections: a case series.
JAC Antimicrob Resist. 2024 Jun 17;6(3):dlae095. doi: 10.1093/jacamr/dlae095. eCollection 2024 Jun.
7
Avoiding misclassification of acute kidney injury: Timing is everything.
Nephrology (Carlton). 2024 Feb;29(2):100-104. doi: 10.1111/nep.14246. Epub 2023 Oct 11.

本文引用的文献

1
Staphylococcus aureus bacteraemia and endocarditis - epidemiology and outcome: a review.
Infect Dis (Lond). 2018 Mar;50(3):175-192. doi: 10.1080/23744235.2017.1392039. Epub 2017 Nov 6.
4
Determining vancomycin Etest MICs in patients with MRSA bloodstream infection does not support switching antimicrobials.
J Infect. 2017 Mar;74(3):248-259. doi: 10.1016/j.jinf.2016.12.007. Epub 2016 Dec 22.
5
Impact of Vancomycin MIC on Treatment Outcomes in Invasive Staphylococcus aureus Infections.
Antimicrob Agents Chemother. 2017 Feb 23;61(3). doi: 10.1128/AAC.01845-16. Print 2017 Mar.
6
Long-term mortality and causes of death associated with Staphylococcus aureus bacteremia. A matched cohort study.
J Infect. 2016 Oct;73(4):346-57. doi: 10.1016/j.jinf.2016.07.005. Epub 2016 Jul 12.
9
Risk factors for long-term mortality of Staphylococcus aureus bacteremia.
Eur J Clin Microbiol Infect Dis. 2016 May;35(5):785-90. doi: 10.1007/s10096-016-2598-8. Epub 2016 Feb 12.
10

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验